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Chronic exposure to arsenic (As), whether directly through the consumption of contaminated drinking water or indirectly
through the daily intake of As-contaminated food, is a health threat for more than 150 million people worldwide. Epidemiological
studies found an association between chronic consumption of As and several pathologies, the most common being cancer-related
disorders. However, As consumption has also been associated withmetabolic disorders that could lead to diverse pathologies, such
as type 2 diabetes mellitus, nonalcoholic fatty liver disease, and obesity. Here, we used ultra-performance liquid chromatography
(UPLC) coupled to electrospray ionization/quadrupole time-of-flight mass spectrometry (ESI-QToF) to assess the effect of
chronic intergenerational As exposure on the lipid metabolism profiles of serum from 4-month-old Wistar rats exposed to As
prenatally and also during early life in drinking water (3 ppm). Significant differences in the levels of certain identified lyso-
phospholipids, phosphatidylcholines, and triglycerides were found between the exposed rats and the control groups, as well as
between the sexes. Significantly increased lipid oxidation determined by the malondialdehyde (MDA) method was found in
exposed rats compared with controls. Chronic intergenerational As exposure alters the rat lipidome, increases lipid oxidation, and
dysregulates metabolic pathways, the factors associated with the chronic inflammation present in different diseases associated with
chronic exposure to As (i.e., keratosis, Bowen’s disease, and kidney, liver, bladder, and lung cancer).
1. Introduction
Arsenic (As) is a chemical metalloid widely distributed in
nature from soil to groundwater; in its inorganic (iAs) form,
it can be highly toxic, especially trivalent arsenic (iAsIII) and
oxidized arsenate (iAsV). Around the world, people are
constantly exposed to this chemical through the con-
sumption of contaminated water and the use of
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contaminated water in agriculture, which contaminates
food. For example, the concentration of As detected in
drinking water in countries in South Asia, as well as
countries such as Argentina, Australia, Hungary, Mexico,
and the United States, is higher than the 10 μg/L permissible
limit established by the World Health Organization (WHO)
[1–3].
Chronic consumption of As has been associated with
diverse diseases, including skin, lung, bladder, and liver
cancers [1], cognitive deficiencies [4], cardiovascular dis-
eases [5], hypertension [6], diabetes mellitus [7–9], and
anemia [10]. Epidemiological studies identify As as a risk
factor for human health [11–13]; until now and even with the
vast number of studies performed (reviewed in [14]), it is not
well known the molecular mechanisms of the toxic and
carcinogenic effects of As. In addition, the number of
metabolic pathways altered by As is too extensive to fully
understand, and there is not a suitable animal model for the
study of the long-term toxicity effects of As exposure [15].
Some of the biochemical pathways altered by As ex-
posure are glucose metabolism [16, 17], protein metabolism
[18], choline metabolism [19], and membrane phospholipid
degradation, which has direct implications in apoptosis [20].
0ese metabolic abnormalities could be the result of an
endocrine signalling disruption. For example, recent studies
in vivo have demonstrated the adverse effects of As exposure
on steroid receptors and endogenous/exogenous hormone-
driven genes [21]. Environmental pollutants, such as As, play
a role in the generation of oxidative stress in cells [22–24].
0e assessment of lipid oxidation is an important marker of
oxidative damage that is associated with membrane phos-
pholipid breakdown, indicative of cellular damage. Con-
centrations of malondialdehyde (MDA) reflect the intensity
of lipid oxidation and have been used by different authors as
a biochemical biomarker of oxidative stress [25, 26].
Chronic exposure to arsenic has been associated with
alterations in the proteome [27, 28] and metabolome in
humans [29–32] and in murine models [33–41]. 0e
mechanism underlying these alterations is not well un-
derstood but could be associated with disruption of some
biological pathways through epigenetic modifications
[42–46]. Metabolomic studies are becoming popular to
explore the altered pathway consequences of long-term
exposures that ultimately lead to the development of various
diseases. Previous metabolomic studies reported the adverse
effects of acute exposure to high As levels (7 days of
exposure to 3mg/kg/day) [33], of chronic exposure to high
As levels (50 ppm for 6 months) [40], and of chronic ex-
posure to lower As (0.5, 2, and 10 ppm for 3 months) [41] in
murine models. Overall, these studies have provided
valuable information on the toxicity and the biochemical
pathways altered by As and have reflected real-life exposure
to As as it occurs in human populations.
0e study of lipid metabolism is crucial in chronic
diseases and metabolic syndrome, where an inflammatory
process takes place. Adiponectin is an adipocyte-derived
hormone that increases insulin sensitivity and has an im-
portant role in the regulation of lipid metabolism, in an
insulin-independent manner [47]. Besides its role in lipid
metabolism, this hormone has beneficial properties, such as
anti-inflammatory and antioxidant. However, the utility of
adiponectin as a candidate biomarker in metabolic syn-
drome prediction and risk assessment seems paradoxical
across studies with uncertain hazard extents for potential
differences regarding ethnic origin, gender, samples, com-
parisons, obesity, or other disease status [48].
In this study, we used ultra-performance liquid chro-
matography (UPLC)-mass spectrometry to analyse the lipid
metabolism of rats exposed to 3 ppm of As in drinking water
(approx. 0.4mg/kg) from gestation, lactation, and
throughout the development until adulthood. 0e As con-
centration used in this work has been used in previous
studies [4, 49, 50] and did not show toxic effects on body
weight, diminution of brood size, or mortality. 0is model
tries to simulate a real-life exposure condition, where people
are chronically exposed to As throughout their lifetimes;
since the placenta is not a barrier to As [19], in-




(i) Establishes the usefulness of untargeted lipidomics
to identify possible biomarkers of exposure to As
(ii) Establishes that increased levels of the lysophos-
phatidylcholines LysoPC (20:4), LysoPC (15:0),
LysoPC (16:0), and LysoPC (18:1) are associated
with As exposure
(iii) Establishes that chronic exposure to As increases
lipid oxidation, which could be associated with
inflammatory processes that lead to chronic dis-
eases, such as cancer, atherosclerosis, and diabetes
(iv) Indicates an effect of chronic and intergenerational
As exposure on lipid alterations, which may be
evaluated and extrapolated in cross-sectional
studies
3. Materials and Methods
3.1. Reagents. High-performance liquid chromatography-
(HPLC-) grade isopropanol, acetonitrile, methanol, and
water were purchased from JT Baker (Brick Town, NJ, USA).
High-purity formic acid (99%) and ammonium acetate
(99%) were provided by 0ermo Scientific (Rockford, IL,
USA), and sodium arsenite was obtained from Sigma-
Aldrich (St. Louis, MO, USA).
3.1.1. 7e Animal Model for Chronic as Exposure. All pro-
cedures performed in studies involving animals were done in
accordance with the ethical standards of the Autonomous
University of San Luis Potosi and were conducted according
to the Guide for the Care and Use of Laboratory Animals.
0is research was conducted under the approval of Ethics
Committee in Research and Teaching from Chemistry
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Faculty of Autonomous University of San Luis Potosi,
Mexico (No. CEID2013-010).
Eight female and four male adult Wistar rats weighing
between 250 and 300 g were randomly placed in four cages in
a ratio of two females to one male and maintained in the
animal facilities under controlled conditions of light
(12 hours light/dark cycle), temperature, and humidity.
Commercial food (LabDiet 5001, St. Louis, MO, USA) and
water were provided ad libitum. As exposure conditions
were carried out according to previous reports [51]. In brief,
a group of three (two females and one male) animals re-
ceived drinking water containing 3 ppm of arsenic as sodium
arsenite (Sigma-Aldrich, St. Louis, MO, USA), approxi-
mately 0.3 to 0.4mg arsenic/kg/day and were identified as
the experimental group. 0e control group received pure
drinking water. Rats from the experimental and control
groups were weighed daily, until weight changes indicated
pregnancy status. After pregnancy detection, rats were
transferred to separate cages, where arsenic exposure con-
tinued throughout gestation and lactation. 0e broods were
weaned after one month and separated by sex. Offspring
from experimental (five female rats: AsF; eight male rats:
AsM) and control groups (five female rats: CF; eight male
rats: CM) continued their treatments until the age of 4
months. At this age, rats from both groups were euthanized
by decapitation. Blood was collected, and serum was isolated
by centrifugation and maintained at − 70°C until its use.
3.1.2. Body Weight and Total Serum Adiponectin
Determination. Rats were weighed at the experimental
endpoint with a technical balance. Weights were recorded in
grams (g). Total serum adiponectin was assessed by enzyme-
linked immunosorbent assay (ELISA) in 96-well plates
(Abcam®, Cambridge, MA, USA) according to the manu-facturer’s instructions. In brief, standards or samples were
added (50 μL/well) to precoated and blocked 96-well plates.
0e plates were incubated for 1.5 h and washed 5 times with
washing buffer (200 μL/well). Biotinylated detection anti-
body was added, and the plates were incubated for 1.5 h and
washed again. Streptavidin-peroxidase conjugate was added
(50 μL/well), and the plates were incubated for 30min at
room temperature. After a final washing step, the plates were
incubated with chromogen substrate (50 μL/well) for 15min.
0en, stop solution was added (50 μL/well), and wells were
read in triplicate using a Fisher Scientific Multiskan FC
microplate reader (450 nm, with a correction wavelength of
650 nm).
3.1.3. Sample Preparation for Mass Spectrometry. Serum
lipid extraction was carried out as described previously [52].
In brief, serum samples were thawed on ice. Immediately,
100 μL of serum was extracted with 300 μL of precooled
isopropanol, vortexed for 1min, and incubated at room
temperature for 10min. 0e extraction mixture was then
stored at − 20°C overnight. After centrifugation at 10 000 g
for 20min, the supernatants were collected, and aliquots of
25 μL were prepared and stored at − 80°C. One aliquot was
transferred into LC vials and diluted to 1 : 20 with
isopropanol/acetonitrile/water (2 :1 :1, v : v : v). Addition-
ally, pooled serum samples were prepared by combining
10 μL of individual sera and were identified as quality
controls (QC). 0ese pooled samples were subjected to the
same procedure as above.
3.1.4. Ultra-Performance Liquid Chromatography (UPLC)-
Mass Spectrometry Method for Lipidomic Analysis.
Samples were analysed as described previously [53, 54]. In
brief, ACQUITYUPLC I-Class (Waters Corp., Milford, MA,
USA) coupled to a XEVO-G2 XS quadrupole time-of-flight
(ToF) mass spectrometer (Waters, Manchester, NH, USA)
with an electrospray ionization source was used. 0e sep-
aration of different lipid classes was done using an UPLC
BEH C18 column (2.1× 100mm, 1.7 μm) using binary
gradient elution of solvents A and B. 0e mobile phase was
A: 10mM ammonium acetate with 0.1% formic acid in
acetonitrile/water (60 : 40, v : v); and B: 10mM ammonium
acetate with 0.1% formic acid in isopropanol/acetonitrile
(90 :10, v : v).0emobile phase was delivered at a flow rate of
0.4mL/min, initially with 60% A, followed by a linear
gradient to 57%A over 2minutes, and then the percentage of
A was decreased to 50% within 0.1min. Over the next 9.9
minutes, the gradient was ramped to 46% A, and the amount
of A was then decreased to 30% in 0.1min. Over 5.9 minutes,
the amount of A decreased to 1% and returned to initial
conditions (60%) at the end of 20 minutes. 0e column
temperature was adjusted to 55°C. 0e injection volume was
5 μL.
Data were acquired in positive electrospray ionization
(ESI+) mode with the capillary voltage set to 2.0 kV, the cone
voltage to 30 eV, and the source temperature to 120°C. 0e
desolvation gas was nitrogen, with a flow rate of 800 L·h− 1
and temperature of 550°C. Data were acquired fromm/z 100
to 2000 in MSE mode in which the collision energy was
alternated between low energy (5 eV) and high energy
(ramped from 15 to 30 eV). As a lock mass for accurate mass
measurements, leucine enkephalin (200 pg/μL in
acetonitrile : water (50 : 50 v/v) + 0.1% formic acid) was in-
fused. For calibration, 0.5mM sodium formate was used.
Four pooled samples (QC) were initially injected to equil-
ibrate the column. One QC sample was injected every five
samples.
3.1.5. Data Acquisition and Statistical Analysis. 0e raw
MSE datasets were acquired in continuum mode and pro-
cessed within UNIFI 1.8.1 (Waters Corp., Milford, USA).
0e analysis parameters were as follows: retention time of
0.5–18min and peak width of 1–30 s. Data within UNIFI
1.8.1 were passed through the apex peak detection and
alignment processing algorithms. 0e intensity of each ion
was normalized with respect to the total ion count (TIC) to
generate a data matrix that consisted of the retention time,
m/z value, and the normalized peak area. In the univariate
analysis, the D’Agostino-Pearson test was performed to
know whether the data showed a normal distribution. A t
test with Welch’s correction was performed to compare
exposed and nonexposed animals. 0is test was used to
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account for the unequal variations between the two groups,
as identified using Levene’s test. Values with p< 0.05 were
considered statistically significant. 0e analysis was per-
formed with SPSS v22 software (Chicago, IL, USA).
0e multivariate data matrix was analysed by using
EZinfo software (Waters Corp., Milford, MA, USA) and
MetaboAnalyst [55]. 0e data were mean-centred and
Pareto-scaled prior to principal component analysis (PCA)
and orthogonal projection to latent structures discriminant
analysis (OPLS-DA). Potential markers of interest were
extracted from the combining variable importance pro-
jection (VIP) plot that was constructed from the loading
plots of OPLS-DA.
0e XCMS Online platform (La Jolla, CA) was also used
for metabolic pathway screening (https://xcmsonline.scripps.
edu). 0e LC-MS/MS raw data from the Waters format were
transformed to the mzXML format with ProteoWizard
software. 0en, the mzXML files were uploaded into the
XCMS Online tool. Using the XCMS Online graphical in-
terface, the pairwise comparison parameters for female rats
(AsF vs CF) and male rats (AsM vs CM), as well as a
comparison between AsF and AsM, were selected to evaluate
differential pathways and the related metabolites that could
influence differential response after arsenic exposure.
Differences between experimental groups were evaluated
by the unpaired t-test with unequal variance with post hoc
Benjamini-Hochberg (FDR) and Bonferroni corrections.
0e level of statistical significance was set at 95% (p< 0.05).
3.1.6. Compound Identification. 0e high-resolution LC-
MS/MS features that were found to be significant in class
separation were further identified by searching accurate
masses against the online available databases, LIPID MAPS
(http://www.lipidmaps.org/), METLIN (https://metlin.
scripps.edu), and the Human Metabolome Database
(http://www.hmdb.ca). 0e identity of compounds was
confirmed by the study of accurate mass and isotopic dis-
tributions for the precursor and product ions formed by
collision induced fragmentation (CID) as previously de-
scribed; a 10 ppm mass tolerance for the precursors and for
theoretical fragmentation searching was established.
Due to the high number of lipid isomers, identification
based only on accurate mass is not enough for an un-
ambiguous identification; for many lipids, the database
search returned several possible compounds. To define the
best hits, other experimental data were used to remove
incorrect candidate structures.0ese data included retention
time, since the chromatographic method used for the
analysis has a well-established retention time range for each
lipid class, and the fragments generated by the high-collision
energy scans on MSE analysis, compared with in silico
fragmentation generated by Unifi software and by manual
assignment of fragments based on known fragmentation
patterns. However, the accurate precursor and fragment
mass data are not enough for the complete assignment of a
lipid structure, since double-bond position and configura-
tion on fatty acid chains, as well the position of fatty acid
chains for lipids containing more than one chain (e.g., PC
and TG), could only be confirmed by injecting reference
standards that were not available for this work. Fragmen-
tation data provided a good confirmation of the number of
carbon atoms and number of double bonds for the fatty acid
chain; some examples for the main lipid classes found in the
samples are shown in the supplementary information.
3.1.7. Determination of Lipid Oxidation. Malondialdehyde
(MDA) concentrations were measured as thiobarbituric acid
reactive substances (TBARS) according to a modified ver-
sion of the procedure previously described [56]. In brief,
250 μL of serum was mixed with 1mL of 1/12 NH2SO4 and
gently shaken. 0en, 0.3mL of 10% phosphotungstic acid
and 1mL of thiobarbituric acid (0.6%) were added to the
tube and heated in a boiling water bath for 1 h. 0e samples
were cooled at room temperature. 0e resulting chromogen
was extracted with 1.5mL n-butyl alcohol by vigorous
shaking. 0e organic phase was separated by centrifugation
at 1600 g for 10min, and its absorbance was recorded at a
wavelength of 530 nm. 0e level of absorbance was con-
verted into nmol/mLMDA from a standard curve generated
with 1,1,3,3-tetraethoxypropane (Sigma-Aldrich, St. Louis,
MO).
4. Results
4.1. Effects of as Exposure on Body Weight and Serum
Adiponectin. In the current study, no differences were
found in water or food consumption, no changes in body
weight were observed in the offspring born from female rats
exposed to As, and no morphological changes were observed
during the development of the pups. Adult exposed rats had
lower body mass than nonexposed rats, although the dif-
ferences were nonsignificant (p> 0.05). However, body
weights of female rats were significantly lower (p< 0.05)
thanmale rats either in exposed or nonexposed groups. Also,
nonsignificant changes (p> 0.05) were observed in the total
level of serum adiponectin in exposed and nonexposed rats.
However, a trend towards an increase was observed, as was
higher adiponectin level, in female rats compared to male
rats (Figure 1). Interestingly, the level of serum adiponectin
correlated negatively with body weight. 0us, animals with
higher serum adiponectin had lower body weight (Figure 1).
4.2. Lipidomic Results. 0e chromatographic method used
for lipid separation has been used before by our group [54]
and showed good retention time reproducibility and was
able to perform the separation between lipid classes, as well
as within classes, with good separation of positional isomers
(Supplementary Figure 1). 0e method’s reproducibility was
evaluated between quality control (QC) injections, which
were run before the samples, and showed excellent re-
producibility for retention time, peak shape, and peak in-
tensity. 0ese were evaluated by direct comparison of
overlaid chromatograms (Supplementary Figure 2) that
showed no drifts in retention time or intensity, reflecting the
stability and reproducibility of the system.
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After the analysis with XCMS online, with criteria of
p< 0.05 and VIP >1.5, we found that 401 and 807 metabolic
features were significantly altered in AsF and AsM, re-
spectively. Among the 401 metabolic features significantly
changed (p< 0.05) in the group of female rats treated with
arsenic, 354 were downregulated and 47 upregulated.
Similarly, from the 807 metabolic features altered in the
group of male rats treated with arsenic, 522 were upregulated
and 285 downregulated (Figure 2). 0e results are available
in the XCMS online platform (Job IDs: 1200223, 1200505,
and 1200737).
In a parallel analysis, a total of 1155 features were de-
tected under the conditions employed for the preprocessing
of the raw data within UNIFI 1.8.1 (Waters Corp., Milford,
MA, USA) and detailed in the Materials and Methods
section. In the PCA score plot, the samples of control groups
were only partially separated from treated groups and
separated regarding sex differences. PCAwas first performed
to discover intrinsic treatment-related clusters within the
datasets. Heat map was also built with the data acquired in
positive mode, reflecting differences regarding sex and in
some metabolites when compared between treated and
unexposed groups (Supplementary Figure 3).
Following this, partial least-squares discriminant anal-
ysis (PLS-DA) and orthogonal partial least-squares dis-
criminant analysis (OPLS-DA) were used to improve
separation among the groups and screen biomarkers.
0e OPLS-DA score plots resulted in unambiguous
intergroup separation. 0e parameters of the obtained
models were satisfied with good quality of variance
explained (R2) and variance predicted (Q2) and are repre-
sented in Figure 3. 0e loading plots (S-Plot) identified the
metabolites with significant differences in abundance be-
tween the study groups. Differential metabolites were se-
lected based on the separation through the OPLS-DA
loadings and VIP. VIP represents the extracted variables’
ability to discriminate between different treatments, and the
variables with VIP values greater than 1.5 were included in
the set of biomarkers analysed.
Lipids that were selected in the OPLS-DA loading S-Plot
were identified as described in Materials and Methods.
Identified lipids with significant changes in expression in
female and male rats exposed to arsenic are summarized in
Table 1. 0e exact measured mass, mass error (ppm), re-
tention time, detected lipid, MSE fragments, and percentage
of changes between groups (fold change), along with the
statistical significance of each change, are detailed in the
table. Metabolomic profiling of serum samples showed
statistically significant changes in glycerophospholipid and
glycerolipid metabolism (p< 0.05). A decrease in the levels
of phosphatidylcholines (PCs) and an increase in the levels
of lysophosphatidylcholines (LysoPCs) were found in the
animals exposed to As and were found to be a more evident
effect in male rats.
0e selected lipids were identified and classified
according to their degree of physicochemical and/or spectral
similarity to published data. MSE data were manually
inspected for the correct identification of major ions, in
conjunction with the use of Lipid MS Predictor software
(http://www.lipidmaps.org/).
0e m/z 496.3396 (ESI+, RT�1.21min) with a reported
prominent fragment ion at m/z 184.0725 was annotated as
LysoPC (16:0) (Figure 4). 0e other minor fragments (m/z
258.1088, m/z 313.2854, m/z 419.3284, and m/z 478.3284)
were also in agreement with experimental and in silico MS/
MS data described in the database METLIN for this com-
pound. LysoPC (16:0) was highly upregulated in male rats
exposed to As in comparison with control rats.
0em/z 482.32407 (ESI+, RT�1.05min) with a reported
prominent fragment ion at m/z 184.0725 was annotated as
LysoPC (15:0) (Figure 5). 0e other minor fragment (m/z
258.10896) corresponded to the acyl loss. LysoPC (15:0) was
highly upregulated in male rats exposed to arsenic in
comparison with control rats.
0e m/z 758.5711 (ESI+, RT� 6.49min) with a reported
prominent ion at m/z 184.0725 was annotated as PC (16:0/
18:2) (Figure 6). 0e other minor fragment (m/z 496.33862)
corresponded to the acyl loss. PC (16:0/18:1) was down-
regulated in male rats exposed to arsenic in comparison with
control rats.
0em/z 904.8347 (ESI+, RT�16.03min) was annotated as
TG (16:0/18:1/20:1) (Figure 7).0ree fragments were generated
as a consequence of the rupture of acyl chains (m/z 631.56710,
605.55007, and 577.51907). TG (16:0/18:1/20:1) was down-
regulated in male rats exposed to arsenic in comparison with
control rats.
From the global metabolomic analysis conducted in
XCMS software, it was predicted that two metabolic path-
ways were dysregulated, namely, the thyroid hormone
















Figure 1: Effects of As exposure on body weight and serum
adiponectin. Female rats (AsF and CF) had nonsignificant higher
levels of adiponectin and lower body weight than male rats (AsM
and CM). Significant differences (p � 0.001) were found between
male and female rats either in exposed or nonexposed groups (two-
way ANOVA with Tukey’s multiple comparison test).


































































































Figure 2: Metabolic features altered by chronic arsenic exposure.0e number of significant alterations is approximately 2-fold in male than
in female rats exposed to As. More metabolites are upregulated in male rats compared to female rats, while more metabolites are
downregulated in female than in male exposed rats. T-test with Welch’s correction was performed to account for the unequal variations
between the two groups.










































































































































































































































































Figure 3: Orthogonal partial least-squares discriminant analysis (OPLS-DA) of determinants in positive and negative ionization modes.
(a) Score plot from OPLS-DA shows group separation between control male rats (CM) and As-exposed male rats (AsM), with quality of
variance explained and variance predicted (R2 (cum)� 99%, Q2 (cum)� 89%). (b) OPLS-DA loadings S-Plot comparing features from CM
rats and AsMmale rats in positive ionization mode. (c) Score plot fromOPLS-DA shows group separation between control female rats (CF)
and As-exposed female rats (AsF), with quality of variance explained and variance predicted (R2 (cum)� 99%, Q2(cum)� 85%). (d) OPLS-
DA loadings S-Plot comparing features from CF rats and AsF rats in positive ionization mode. Each spot in S-Plot corresponds to a feature
with characteristic m/z ratio and retention time. 0e metabolites marked in red were treated as putative biomarkers of As exposure.










Fold change (p value)a
AsF vs CF AsM vs CM
LysoPC (20:4) 544.3395 − 0.5 0.99 +H 184.07268, 258.10896 +3.71(0.32231) +1.4 (0.021)
LysoPC (15:0) 482.3238 − 0.7 1.05 +H 184.10804, 258.10896 +1.1 (0.69) +2.44(6.05E − 06)b,c
LysoPC (16:0) 496.3397 0.0 1.22 +H 184.07273, 258.1101 +15 (0.225) +3.38(7.27E − 05)b
LysoPC (18:1) 522.3552 − 0.5 1.27 +H 184.07273, 258.1101 +191 (0.098) +1.77(1.4E − 04)b
PC (O-16:0/1:0) 510.3555 0.2 1.43 +H 492.34431 − 1.0 (0.988) +2.54(4.94E − 06)b,c
PC (20:4/16:0) 782.5709 5.0 6.21 +Na 184.07263, 496.33883 − 10000(5.27E − 03) − 1.5 (0.034)
PC (16:0/18:2) 758.5711 2.2 6.51 +H 184.07266, 496.33862, 502.32807 − 2.03 (0.09) − 1.8 (0.043)
TG (16:0/18:1/




22:5) 920.7724 2.5 14.96 +NH4 647.5034, 625.5191, 573.48693 +1.5 (0.032) +1.3 (0.06)
TG (16:1/18:2/
22:6) 918.7576 − 9.5 14.57 +H 647.49851, 621.48725, 573.48690
+1.7
(9.52E − 03) +1.0 (0.97)
3-Deoxyvitamin
D3 369.3510 − 0.1 15.72 +H
287.23, 233.2252, 215.1783,
161.1315, 147.1159 +1.5 (0.0624)
+1.61
(4.0E − 04)b
aFC, fold change in the specified comparisons. “+” indicates upregulation and “− ” indicates downregulation. bp values significant also due to FDR. cp values
significant also to Bonferroni test correction.
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4.3.Determinationof LipidOxidation. To evaluate the effects
of As exposure on lipid oxidation, we carried out an analysis
of lipid oxidation in serum. Lipid oxidation was increased in
treated animals with respect to the controls (p< 0.05), as
determined by the MDA method. Figure 8 shows the results
of lipid oxidation determination.
5. Discussion
In the present study, we found that chronic and in-
tergenerational exposure to As has an effect on the lipid
metabolism, significantly increasing the levels of the lyso-
phosphatidylcholines: LysoPC (20:4), LysoPC (15:0), LysoPC
(16:0), and LysoPC (18:1). Chronic exposure to As also in-
creases lipid oxidation, which could be associated with in-
flammatory processes that lead to chronic diseases. Previously,
Wang et al. provided novel evidences to support the associ-
ation between As exposure and metabolic disruption, con-
tributing to understanding the mechanism of chronic arsenic
toxicity. Possible role of lipid alterations and their precursors,
mediating inflammatory process associated with toxicity after
As exposure, is briefly speculated in the present work.
Here, the effect of chronic and intergenerational As
exposure on rat lipid metabolism was evaluated in an in vivo
model.0emodel of exposure employed in the present work
has been well characterized by our group [51, 57–60] and
represents an important reference for neurotoxicity and
oxidative damage. In these previous articles, all the As
quantifications were performed in brain tissue of As-ex-
posed rats through validated methods in our laboratory such
as atomic fluorescence or by inductively coupled plasma-
sector field mass spectrometry (ICP-SFMS), and NIST
standards were used to assess quality assessments and
quality controls.
To our knowledge, although several studies have fo-
cussed on the reproductive and carcinogenic effects of
transplacental As exposure [61–63], scarce data are available
about the intergenerational effects of arsenic on lipid
metabolism in animal models. States and colleagues dem-
onstrated that transplacental arsenic exposure in mice alters
developmental programming in the foetal liver, leading to an
enduring stress and proinflammatory response postnatally,
which may contribute to early onset of atherosclerosis [64].
Ditzel and colleagues demonstrated that in utero and con-
tinuous early-life exposure to AsIII disrupted normal
metabolism and elevated the risk for fatty liver disease in
mice maintained on a high-fat diet, suggesting that in-
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Figure 4: Low-collision (a) and high-collision (b) energy exact mass spectra of LysoPC (16:0). 0e low-energy spectrum only contains the
precursor ion at m/z 496.34029, whereas in the high-energy spectrum, various diagnostic fragments appear as the loss of the FA chain at
258.1101. Also, the major fragment ion at m/z 184.07273 can be seen corresponding to the polar head group.













































Channel name: high energy: time 6.4917 ± 0.1826 minutes
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Figure 6: Low-collision (a) and high-collision (b) energy exact mass spectra of PC (16:0/18:2). 0e low-energy spectrum only contains the
precursor ion at m/z 758.57038, whereas in the high-energy spectrum, various diagnostic fragments appear as the loss of the various FA
chains atm/z 496.3410 and 478.32789 (the water loss) and 502.32807, which belong to the water loss of the chain atm/z 520.3407. Also, the
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Figure 5: Low-collision (a) and high-collision (b) energy exact mass spectra of LysoPC (15:0). 0e low-energy spectrum only contains the
precursor ion at m/z 482.32407, whereas in the high-energy spectrum, various diagnostic fragments appear as the loss of the FA chain at
258.10896. Also, the major fragment ion at m/z 184.10804 can be seen corresponding to the polar head group.
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and who remain exposed through eating aWestern-style diet
may be at increased risk for metabolic disease later in life
[65].
Arsenic influences many diverse disease processes, such
as cell signalling, cell cycle control, oxidative stress, and
DNA repair [66–69]. Important dose-, time-, and tissue-
specific differences in the effects of As, as well as important
gene-environment and coexposure interactions, have been
reported in several studies [70–75]. 0e effect of As on lipid
and amino acid metabolism has been previously demon-
strated [41], intimately associated with fatty acid beta-oxi-
dation and amino acid metabolic abnormalities.
In our study, we focused mainly on the lipid alterations
after chronic and intergenerational exposure to low doses of
arsenic in drinking water. In this lipidomic study, we
identified principally three classes of lipids that were sig-
nificantly altered: glycerophospholipids (lysophospholipids
and phosphatidylcholines), glycerolipids (triglycerides), and
sterol lipids (3-deoxyvitamin D3).
0e effect of As on lipid metabolism has been demon-
strated in different models. Carlson and colleagues dem-
onstrated, in zebrafish exposed to As, that two genes
involved in lipid transport/metabolism (carnitine O-octa-
noyltransferase (crot) and 3-hydroxy-3-methylglutaryl-CoA
synthase 1 (hmgcs1)) were responsive after 7 days of ex-
posure to 10 ppb sodium arsenite in water [76]. Sex-specific
and duration-dependent responses were also observed [77].
In addition, Garciafigueroa demonstrated that 5-week ex-
posure of mice to 100 μg/L of arsenic in drinking water
reduced the adipose tissue expression of perilipin (PLIN1, a
lipid droplet coat protein), which regulates lipid storage and
lipolysis [20].
In relation to the glycerophospholipids, we observed a
decrease in the levels of different phosphatidylcholines (PC)
in a sex-specific manner, that is, only in AsF, and an increase
in the level of lysophosphatidylcholines (LysoPCs). LysoPCs
are generated by free radical-catalyzed oxidation of poly-
unsaturated PCs to oxidatively truncated phosphatidyl-
cholines (oxPCs); oxPCs are hydrolysed by the platelet-
activating factor acetylhydrolase, a phospholipase (PL) A2
that exists in plasma associated with LDL [78]. Under
pathological conditions, overstimulation of phospholipase A
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Figure 7: Low-collision (a) and high-collision (b) energy exact mass spectra of TG (16:0/18:1/20:1). 0e low-energy spectrum only contains
the precursor ion atm/z 904.53508, whereas in the high-energy spectrum, various diagnostic fragments appear as the loss of the various FA
















Figure 8: Lipid oxidation (MDA level) in the serum of rats exposed
to 3 ppm of As in drinking water. ∗∗∗p � 0.0002 vs. control (T-test).
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accumulation of LysoPCs. LysoPCs can also be formed by
the action of lecithin-cholesterol acyltransferase (LCAT) in
plasma. Wang and colleagues reported a marked increase in
the level of LysoPCs and elevated expression of hepatic lcat
in male rats treated with 10 ppm arsenic, suggesting that
arsenic exposure may disrupt the transformation process of
LysoPCs, leading to their accumulation [41].
In general, lysophospholipids are involved in many
physiological processes, including inflammation [79].
LysoPCs have a role as proinflammatory molecules,
attracting thromboxanes, leukotrienes, and prostaglandins.
Elevated levels of LysoPCs have been linked to the car-
diovascular complications associated with diabetes [80],
atherosclerosis, ischaemia [78], renal failure during hemo-
dialysis [81], rheumatoid arthritis [82], asthma [83], sepsis
[84], hyperlipidaemia [85], endometriosis [86], and psoriasis
[87].
With regard to the modulation in glycerolipid meta-
bolism, the results are not conclusive. Several studies have
suggested the implication of arsenic in metabolic dysregu-
lation, based on the effect of arsenic exposure on triglyceride
production and lipid metabolism [88]. In our study, three
identified species of glycerolipids (TG) were differentially
regulated (one downregulated and two upregulated) be-
tween female andmale rats exposed to As (Table 1).0e level
of expression of one of these TG was significantly different
between female and male rats.
When we analysed the global metabolic perturbation
observed in the present work and its relation to As exposure,
an increase was observed in ametabolite putatively predicted
to be 3-demethylubiquinol, which is found in the ubiquinol
biosynthesis pathway [89]. It is interesting that ubiquinone
derivatives, including 3-demethylubiquinol-10 (reduced
form of coenzyme Q10) and 6-methoxy-3-methyl-2-all-
trans-decaprenyl-1,4-benzoquinol, were upregulated, sug-
gesting that mitochondria were undergoing substantial
oxidative stress, which eventually leads to cell death. An
increase in 3-demethylubiquinol could suggest inhibition of
3-demethylubiquinol 3-O-methyltransferase by a mecha-
nism of negative feedback, interrupting the synthesis of
ubiquinol-10, which is the reduced form of ubiquinone and
responsible for preventing lipid oxidation. Recent in vitro
and in vivo studies have provided evidence that coenzyme
Q10 is involved in inflammatory processes and lipid
metabolism via gene expression changes [90].
In the present work, we also demonstrated that lipid
oxidation was increased in the serum of arsenic exposed rats
(Figure 8). It has been described that oxidative modifications
of lipids occur during inflammatory processes and lead to
the formations and accumulations of oxidized lipids that
produce cellular reactions such as apoptosis and chronic
inflammatory reactions, which are considered critical factors
for most chronic diseases. Oxidized lipids in cellular
membrane and lipoproteins have been considered as an
endogenous class of damage-associated molecular patterns
(DAMPs), which share common structural motifs with
microbial pathogen-associated molecular patterns (PAMPs).
0us, oxidized lipids may activate the same pattern recog-
nition receptors (PRRs) on immune and vascular cells. It has
been increasingly recognized that elicitation of innate im-
mune response by these oxidized lipids can be physiological
(homeostatic) or pathophysiological (adverse) depending on
the biological context and duration of the immune activa-
tion. In this work, we do not have any immunological
marker, but it will be considered in future investigations
[91]. Lipid oxidation-derived products are key players in the
initiation and progression of atherosclerotic lesions and
inflammatory process. Oxidized lipids, derived from oxi-
datively modified low-density lipoproteins (LDLs), which
accumulate in the intima, strongly modulate inflammation-
related gene expression, through involvement of various
signalling pathways [92].
Arsenic increases lipid oxidation in the liver, kidney, and
heart associated with a depletion of GSH [93]. We could
speculate that a chronic inflammatory process resulting
from As exposure is responsible for the metabolic changes
found in lipid metabolism.
Glycolipids, phospholipids (PLs), and cholesterol (Ch)
are targets of potential lethal oxidative modification. Under
toxic conditions, such as exposure, the extent of oxidative
damage overwhelms cellular repair capacity, and the cells
induce apoptosis or necrosis, facilitating the development of
various pathological states and accelerated ageing. Phos-
phatidylcholine hydroperoxide (PCOOH) is the primary
product of lipid oxidation: it undergoes nonenzymatic re-
actions, leading to the formation of 4-hydroxynonenal (4-
HNE) and malondialdehyde (MDA), secondary products of
lipid oxidation [94]. 0ese lipid oxidation products induce
oxidative stress and are involved in the pathogenesis of a
number of degenerative diseases; consequently, they are
considered to be biomarkers of oxidative stress. LysoPCs are
one of the numerous lipid products formed during the
oxidation of low-density lipoprotein (LDL).
Another important finding in our study is the predictive
dysregulation of thyroid hormone metabolism. As is a po-
tent endocrine disruptor, altering steroid hormone receptor-
(SR-) mediated gene regulation for all five steroid receptors
(SRs) (i.e., the receptors for glucocorticoid (GR), androgen
(AR), progesterone (PR), mineralocorticoid (MR), and
oestrogen (ER)) and two members of the larger nuclear
hormone receptor superfamily, the retinoic acid (RA) re-
ceptor (RAR) and the thyroid hormone (TH) receptor (TR),
at very low concentrations in cell culture and in whole-
animal models [72, 73, 95, 96]. 0yroid hormones (THs) are
also a major factor controlling metabolic rates in mammals;
these hormones stimulate both lipogenesis and lipolysis,
thereby provoking thermogenesis and an increase of the rate
of both anabolic and catabolic reactions dependent on time
and substrate. On the contrary, fat metabolism is affected by
THs. 0e increase in TH levels modifies the composition of
membrane phospholipids [97], increasing the degree of
unsaturation particularly in the mitochondrial membranes
[88], making them more susceptible to free radical attack
[98] and resulting in augmented lipid oxidation in
mitochondria.
Important differences in the levels of expression of
metabolites were found in our work between AsM and AsF
rats. Considering the effect of arsenic as an endocrine
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disruptor [95], these differences could be attributed to
oestrogen hormones, although this could not be demon-
strated here. Different histone methylation patterns have
been observed between men and women after arsenic ex-
posure [99]. Additionally, a recent in vivo study demon-
strated sex-specific metabolomic changes in As (+3
oxidation state) methyltransferase (As3mt)-knockout mice
exposed to iAs, raising the possibility of a role for sex
hormones in the regulation of arsenite-methyltransferase-
catalyzed arsenic metabolism [38].
In the study of biochemical alterations related to ar-
senic exposure, animal models are a powerful tool. How-
ever, there is no ideal model for reproducing human real
exposure and the effects caused on metabolic perturba-
tions. For this reason, it is necessary to mention some of the
straights and limitations of the animal model employed in
the present work. Rats do have metabolic, distribution, and
excretion functions similar to those in humans and have
been valuable models for investigating the effects of arsenic.
However, extrapolating the rat model to humans requires
an understanding of the differences between the meta-
bolism and toxicokinetics of arsenicals in these species.
Rats have longer retention time of arsenic in the blood
because arsenic binds to rat hemoglobin (due to an extra
cysteine on the a-globin chain of the hemoglobin, which
has a strong affinity to trivalent arsenic) [100]. In another
study, it was demonstrated that hepatocytes from rats,
macaques, and dogs had much greater capacities to
methylate iAs than do hepatocytes from humans, mice, or
rabbits [101].
6. Conclusions
0e results obtained in our work demonstrate a clear effect
of As exposure on lipid metabolism and related pathways in
a model of chronic and intergenerational exposure. 0e
prolonged As exposure, before and during pregnancy and
during the neonatal development, could result in lipid ox-
idation and the degradation of membrane lipids, which was
more evident in male rats in comparison to female rats.
0us, serum phospholipids might be biomarkers for ex-
posure to As; however, these results need to be extrapolate in
future studies conducted in humans.
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Supplementary Figure 1: base peak UPLC-TOF MS chro-
matogram of a rat serum extract using electrospray ioni-
zation in positive mode; different lipid classes elute in
different elution time windows. For the experimental details,
see Materials and Methods. PC: phosphatidylcholines; PG:
phosphatidylglycerol; PE: phosphatidylethanolamine; SM:
sphingomyelin; DG: diacylglycerides; CE: cholesterol esters;
TG: triacylglycerides. Supplementary Figure 2: overlaid
chromatograms of quality controls (QC) showing good
reproducibility for retention time, peak shape, and peak
intensity. (a) QCFCT: overlaid chromatograms of three
replicates of QC from female control group. (b) QCFAS:
overlaid chromatograms of three replicates of QC from
female exposed group. (c) QCMCT: overlaid chromato-
grams of three replicates of QC frommale control group. (d)
QCMAS: overlaid chromatograms of three replicates of QC
from female control group.0e conditions employed for QC
acquisition data were the same for the samples. Supple-
mentary Figure 3: heat map visualization constructed based
on the differential metabolites of importance for the sera of
As-treated groups. 0e heat map was constructed based on
the potential candidates of importance, which were
extracted with PLS-DA analysis. Rows, metabolites; col-
umns, samples. Colour key indicates metabolite expression
value: lowest (green) and highest (red). Variable differences
are revealed between the control groups and As-exposed and
between sexes. (Supplementary Materials)
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